Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2023-07-28 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
유상증자최종발행가액확정(주주배정후 실권주 일반공모)
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from Clinomics regarding the final issuance price for a paid-in capital increase (rights offering). It details the number of shares, the final price per share, and the calculation methodology. This falls under the category of capital structure changes and share issuance announcements, which is best classified as 'SHA' (Share Issue/Capital Change).
2023-07-28 Korean
[기재정정]주요사항보고서(유무상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) from Clinomics, specifically detailing a decision regarding a capital increase (유무상증자결정). It outlines the terms of both paid-in (유상증자) and bonus (무상증자) capital increases, including share issuance prices, allocation ratios, and subscription dates. This type of filing is a formal announcement of a change in the company's capital structure and share issuance, which falls under the 'Share Issue/Capital Change' category.
2023-07-28 Korean
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고서' (Securities Registration Statement Amendment) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the issuance price for a capital increase (rights offering/public offering). This document is a formal regulatory filing required for capital raising activities, specifically detailing the adjustment of share prices and the use of proceeds. It fits the 'Capital/Financing Update' (CAP) category as it pertains to the company's financing activities and capital structure changes.
2023-07-28 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 1% confidence The document is a 'Correction Report' (정정신고) for an 'Investment Prospectus' (투자설명서) filed by Clinomics. It details changes to the offering price, total offering amount, and the use of proceeds for a capital raise (rights offering). Since this is a formal regulatory filing regarding a capital increase and the amendment of a prospectus, it falls under the category of Capital/Financing Update.
2023-07-28 Korean
[기재정정]증권신고서(지분증권) (2023.07)
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by Clinomics. It details a capital increase (rights offering/paid-in capital increase) and includes comprehensive risk factors, financial information, and management discussion. This is a formal regulatory filing required for public offerings of securities. In the context of the provided categories, this fits best as a Regulatory Filing (RNS) as it is a formal submission to the financial regulator (FSS/DART) regarding a capital-related regulatory process.
2023-07-27 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 1% confidence The document is a '투자설명서' (Investment Prospectus) for Clinomics, which is a formal regulatory filing required for a capital increase (rights offering). It contains detailed information about the offering, risk factors, and financial status, which is characteristic of a prospectus filed with the financial regulatory authority (DART). This falls under the category of capital/financing updates.
2023-07-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.